Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01)

The summary for the Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research applications from clinicians, epidemiologists, geneticists, statisticians, and translational researchers working in the field of cancer control and prevention to improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data; develop new models for cancer risk and prognosis; and validate new models and evaluate their utility in research and clinic settings. To explore this opportunity, the NCI Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Treatment and Diagnosis (DCTD) encourage applications for research projects to develop, apply, and evaluate new and existing cancer risk and prognostic prediction models for use by researchers, clinicians, and the general public. This FOA is designed to provide a mechanism of support for investigators to address two major challenges in model development, which are: integrating diverse types of data (e.g., clinical, demographic, pathologic, environmental, epidemiologic, outcomes, and genetic data from varied data marts or warehouses); and ensuring adequate validation (i.e., using multiple separate populations to define sensitivity, specificity, and positive and negative predictive values). Applications that are focused on the identification and characterization of prognostic/diagnostic markers are not appropriate for this FOA. Mechanism of Support. This FOA will utilize the research project (R01) grant mechanism, and runs in parallel with a FOA of identical scientific scope, PA-10-026 that encourages applications under the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.